Course of depressive symptoms over follow-up. Findings from the National Institute of Mental Health Treatment of Depression Collaborative Research Program.

Department of Psychiatry and Human Behavior, Brown University, Providence, RI 02906.
Archives of General Psychiatry (Impact Factor: 13.75). 11/1992; 49(10):782-7.
Source: PubMed

ABSTRACT We studied the course of depressive symptoms during an 18-month naturalistic follow-up period for outpatients with Major Depressive Disorder treated in the National Institute of Mental Health Treatment of Depression Collaborative Research Program. The treatment phase consisted of 16 weeks of randomly assigned treatment with the following: cognitive behavior therapy, interpersonal therapy, imipramine hydrochloride plus clinical management (CM), or placebo plus CM. Follow-up assessments were conducted at 6, 12, and 18 months after treatment. Of all patients entering treatment and having follow-up data, the percent who recovered (8 weeks of minimal or no symptoms following the end of treatment) and remained well during follow-up (no Major Depressive Disorder relapse) did not differ significantly among the four treatments: 30% (14/46) for those in the cognitive behavior therapy group, 26% (14/53) for those in the interpersonal therapy group, 19% (9/48) for those in the imipramine plus CM group, and 20% (10/51) for those in the placebo plus CM group. Among patients who had recovered, rates of Major Depressive Disorder relapse were 36% (8/22) for those in the cognitive behavior therapy group, 33% (7/21) for those in the interpersonal therapy group, 50% (9/18) for those in the imipramine plus CM group, and 33% (5/15) for those in the placebo plus CM group. The major finding of this study is that 16 weeks of these specific forms of treatment is insufficient for most patients to achieve full recovery and lasting remission. Future research should be directed at improving success rates of initial and maintenance treatments for depression.

  • Source
  • [Show abstract] [Hide abstract]
    ABSTRACT: The acute efficacy of selective serotonin reuptake inhibitors (SSRIs) in the treatment of major depressive disorder (MDD) is well established; however their role in longer-term prevention of recurrence remains unconfirmed. This study aims at examining: the prophylactic efficacy of four commonly used SSRIs in MDD in a naturalistic setting with long-term follow-up, the effect of concomitant cognitive behavioral therapy (CBT), and the predictors of outcome. In a prospective cohort study, 387 patients who either remitted or responded following treatment with four different SSRIs-fluoxetine, escitalopram, sertraline and paroxetine-were followed up over several years. During an average follow-up period of 34.5 months, 76.5% of patients experienced MDD recurrence. Escitalopram and fluoxetine showed a numerically higher prophylactic efficacy than paroxetine and sertraline but the difference was statistically insignificant. The prophylactic efficacy for SSRI-only treatment was limited, with a recurrence rate of 82.0%, compared to 59.0% of patient recurrence rate in concomitant Cognitive Behavioral Therapy (CBT). The relatively small size of the CBT group and the lack of randomization may undermine the extrapolation of its findings to clinical practice. Nevertheless, the study preliminary data may help in defining the clinical utility of antidepressants and CBT in the prophylaxis from MDD recurrence. Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.
    Psychiatry Research 11/2014; DOI:10.1016/j.psychres.2014.11.022 · 2.68 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The validity and utility of terms such as evidence-based in relation to clinical practice in psychology are here subjected to critical analysis. The method of the analysis is to closely review the findings of a major study investigating treatment efficacy with depression and to consider how seriously these findings compromise the status of cognitive behavioural therapy (CBT) as evidence-based with respect to its efficacy for treatment of depression. It is concluded that this study raises serious doubts as to whether CBT has superior efficacy, compared with other treatment approaches, and also raises doubts as to whether treatment effects that can be detected derive from treatment-specific factors. It is argued that there is little basis for according CBT a privileged status as evidence-based in relation to treatment of depression. The broader implication of this conclusion for the development of treatment guidelines or practitioner training standards is discussed.
    Australian Psychologist 07/1998; 33(2). DOI:10.1080/00050069808257386 · 0.61 Impact Factor


Available from
Jul 24, 2014